ANI Pharmaceuticals (ANIP) Competitors $65.22 +1.66 (+2.61%) Closing price 04:00 PM EasternExtended Trading$65.25 +0.03 (+0.05%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ANIP vs. LNTH, TLX, NUVL, AXSM, AKRO, PCVX, ADMA, KRYS, ZLAB, and RYTMShould you be buying ANI Pharmaceuticals stock or one of its competitors? The main competitors of ANI Pharmaceuticals include Lantheus (LNTH), Telix Pharmaceuticals (TLX), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), Vaxcyte (PCVX), ADMA Biologics (ADMA), Krystal Biotech (KRYS), Zai Lab (ZLAB), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry. ANI Pharmaceuticals vs. Its Competitors Lantheus Telix Pharmaceuticals Nuvalent Axsome Therapeutics Akero Therapeutics Vaxcyte ADMA Biologics Krystal Biotech Zai Lab Rhythm Pharmaceuticals Lantheus (NASDAQ:LNTH) and ANI Pharmaceuticals (NASDAQ:ANIP) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment. Do institutionals & insiders have more ownership in LNTH or ANIP? 99.1% of Lantheus shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 1.5% of Lantheus shares are owned by company insiders. Comparatively, 11.1% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media refer more to LNTH or ANIP? In the previous week, Lantheus had 4 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 10 mentions for Lantheus and 6 mentions for ANI Pharmaceuticals. Lantheus' average media sentiment score of 1.04 beat ANI Pharmaceuticals' score of 0.81 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ANI Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate LNTH or ANIP? Lantheus currently has a consensus price target of $130.50, indicating a potential upside of 63.90%. ANI Pharmaceuticals has a consensus price target of $80.13, indicating a potential upside of 22.85%. Given Lantheus' higher probable upside, equities research analysts clearly believe Lantheus is more favorable than ANI Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantheus 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00ANI Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, LNTH or ANIP? Lantheus has higher revenue and earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLantheus$1.53B3.59$312.44M$3.5222.62ANI Pharmaceuticals$614.38M2.30-$18.52M-$1.27-51.35 Which has more volatility & risk, LNTH or ANIP? Lantheus has a beta of 0.12, meaning that its stock price is 88% less volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Is LNTH or ANIP more profitable? Lantheus has a net margin of 16.55% compared to ANI Pharmaceuticals' net margin of -3.12%. Lantheus' return on equity of 36.99% beat ANI Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Lantheus16.55% 36.99% 20.55% ANI Pharmaceuticals -3.12%21.35%7.52% SummaryLantheus beats ANI Pharmaceuticals on 12 of the 16 factors compared between the two stocks. Get ANI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANIP vs. The Competition Export to ExcelMetricANI PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.38B$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-51.3521.3126.1719.90Price / Sales2.30278.47414.67113.66Price / Cash8.3741.4736.1356.90Price / Book3.417.518.055.38Net Income-$18.52M-$55.05M$3.15B$248.50M7 Day Performance-1.05%2.45%1.85%2.97%1 Month Performance5.35%7.33%4.81%6.02%1 Year Performance4.12%5.38%34.86%20.39% ANI Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANIPANI Pharmaceuticals3.7226 of 5 stars$65.22+2.6%$80.13+22.9%+0.2%$1.38B$614.38M-51.35600LNTHLantheus4.4467 of 5 stars$80.81+2.0%$130.50+61.5%-0.7%$5.59B$1.53B22.96700Positive NewsTLXTelix PharmaceuticalsN/A$16.39-4.4%$22.00+34.2%N/A$5.54B$516.72M0.00N/AGap DownHigh Trading VolumeNUVLNuvalent3.7277 of 5 stars$75.98+1.3%$115.50+52.0%+3.3%$5.46BN/A-17.3140Analyst UpgradeInsider TradeAXSMAxsome Therapeutics4.6769 of 5 stars$101.65+1.0%$172.33+69.5%+27.1%$4.96B$385.69M0.00380Analyst RevisionAKROAkero Therapeutics3.6224 of 5 stars$54.03-0.3%$82.50+52.7%+122.0%$4.32BN/A0.0030PCVXVaxcyte1.7866 of 5 stars$33.25+1.2%$136.50+310.5%-57.2%$4.29BN/A-8.33160News CoveragePositive NewsADMAADMA Biologics4.0975 of 5 stars$17.87+0.7%$27.67+54.8%+54.8%$4.24B$426.45M31.68530KRYSKrystal Biotech4.6224 of 5 stars$137.92+4.1%$211.13+53.1%-23.7%$3.99B$290.52M33.15210Analyst RevisionHigh Trading VolumeZLABZai Lab3.3948 of 5 stars$36.01+4.2%$47.37+31.5%+103.4%$3.97B$398.99M-14.461,869Positive NewsAnalyst ForecastInsider TradeAnalyst RevisionGap UpRYTMRhythm Pharmaceuticals3.7939 of 5 stars$62.13+0.2%$76.62+23.3%+53.4%$3.95B$130.13M-22.11140 Related Companies and Tools Related Companies Lantheus Alternatives Telix Pharmaceuticals Alternatives Nuvalent Alternatives Axsome Therapeutics Alternatives Akero Therapeutics Alternatives Vaxcyte Alternatives ADMA Biologics Alternatives Krystal Biotech Alternatives Zai Lab Alternatives Rhythm Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANIP) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ANI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANIP Stock Alerts